Aclaris Therapeutics, Inc. (ACRS) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Aclaris Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$3.71HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.71HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — ACRS vs PHAT
growth of $100 · dividends reinvested · last 7yACRS +154.2% (+14.3%/yr)PHAT -72.8% (-17.0%/yr)ACRS compounded faster over this window
Log scale — wide-divergence pair
ACRS PHAT
ACRS vs PHAT: by the numbers
- •PHAT is the larger company ($542M vs $518M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -921.50% net margin).
Metrics side by side
Valuation
| Metric | ACRS | PHAT |
|---|---|---|
| P/S ratio | 63.04 | 2.26 |
| P/B ratio | 4.16 | N/A |
Profitability
| Metric | ACRS | PHAT |
|---|---|---|
| Gross margin | 73.28% | 82.92% |
| Operating margin | -975.91% | -91.36% |
| Net margin | -921.50% | -41.34% |
| ROE | -60.79% | N/A |
| ROIC | -56.99% | -23.45% |
Growth (annualized)
| Metric | ACRS | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | N/A |
| Total return CAGR (5Y) | -24.23% | -26.93% |
Frequently asked
- How have ACRS and PHAT total returns compared?
- Over the past 5 years, ACRS delivered -24.23% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.